Biotechs line up for a busy week of IPOs

As skeptics and enthusiasts banter back and forth over whether the biotech industry is seeing a bubble on Wall Street, a number of biotechs aren't waiting around for a definitive answer. In a busy week for IPOs in general, four biotechs are planning to go public this week. Seres Therapeutics leads the bunch with a $100 million offering to support its work on the microbiome. Microstent glaucoma devicemaker Glaukos, a medical device company, is also up alongside Cambridge, MA-based Catabasis and Germany's Pieris, the latest European outfit to land at Nasdaq in search of investors cash. Story

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.